Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD, specifically evaluating nivolumab plus rucapari...

Full description

Bibliographic Details
Main Authors: Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr
Format: Article
Language:English
Published: BMJ Publishing Group 2022-08-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/8/e004761.full

Internet

https://jitc.bmj.com/content/10/8/e004761.full

Similar Items